RxDoctor Payments DataLook up a doctor →

Thomas Smith, MD

Neurology · Mechanicsville, VANPI 1952372112

Payments from drug & device makers

$182,187in general payments, 2019–2025

Across 834 payments — averaging $218.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$121K
  • Sanofi$25K
  • Teva Pharmaceuticals USA, Inc.$15K
  • E.r. Squibb & Sons, L.L.C.$9K
  • Bristol Myers Squibb$4K
  • AstraZeneca$1K
  • plus $8K from 53 others

What the payments were for

  • Consulting fees$5,9053%
  • Speaking & faculty fees$155,23585%
  • Travel & lodging$5,0923%
  • Food & beverage$15,0888%
  • Education$8670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)275$120,656
Sanofi56$24,512
Teva Pharmaceuticals USA, Inc.48$14,965
E.r. Squibb & Sons, L.L.C.13$8,722
Bristol Myers Squibb45$4,150
AstraZeneca(2 entities)31$1,261
UCB, Inc.43$795
Biogen41$677
Novartis44$602
Amgen(2 entities)17$447
SK Life Science, Inc.10$428
EMD Serono, Inc.27$344
Biohaven Pharmaceuticals, Inc.13$340
Genentech USA, Inc.12$329
Lilly USA, LLC6$326
Lundbeck LLC7$298
Kyowa Kirin, Inc.10$242
Sunovion Pharmaceuticals Inc.12$221
Neurelis, Inc.5$221
Biohaven Pharmaceutical Holding Company Ltd.7$218
Eisai Inc.5$190
ANI Pharmaceuticals, Inc.4$187
Livanova USA, Inc.8$186
Greenwich Biosciences, Inc.7$131
Mallinckrodt Hospital Products Inc.5$115
MDD US Operations, LLC6$113
Supernus Pharmaceuticals, Inc.6$108
Banner Life Sciences, LLC5$107
TG Therapeutics, Inc.2$107
Johnson & Johnson(2 entities)5$104
Amneal Pharmaceuticals LLC6$96
CSL Behring5$92
Pfizer5$90
Grifols USA, LLC4$73
Acadia Pharmaceuticals Inc3$67
Neurocrine Biosciences, Inc.3$63
Acorda Therapeutics, Inc4$61
Jazz Pharmaceuticals Inc.2$45
Otsuka America Pharmaceutical, Inc.2$39
GRT US Holding, Inc.2$38
Tanabe Pharma America, Inc.2$37
Ipsen Biopharmaceuticals, Inc1$36
Avion Pharmaceuticals2$36
Medtronic(2 entities)2$33
Corium, LLC2$33
Abbott1$23
Bayer1$21
Catalyst Pharmaceuticals, Inc.1$20
Promius Pharma LLC1$20
Upsher-smith Laboratories LLC1$19
Impel Pharmaceuticals Inc.1$18
Cala Health, Inc.1$18
Vanda Pharmaceuticals Inc.1$18
GE HealthCare1$18
Adamas Pharmaceuticals, Inc.1$17
Alnylam Pharmaceuticals Inc.1$15
Averitas Pharma Inc.1$14
Avanir Pharmaceuticals, Inc.1$13
Assertio Therapeutics, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$182,187 in reported general payments places this provider in the 90th percentile of 474 neurology providers in Virginia.

See all neurology providers in Virginia

Medicare billing

Part B allowed, 2024
$219,048
Medicare patients
1,075
Services billed
1,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate28$309,477
AubagioTeriflunomide19$170,389
Avonex Pen (4 Pack)Interferon Beta-1a12$157,013
GilenyaFingolimod Hcl12$119,923
UbrelvyUbrogepant77$108,682
AustedoDeutetrabenazine12$88,850
Teriflunomide36$75,918
Dimethyl Fumarate26$62,592
Nurtec OdtRimegepant Sulfate42$53,878
FingolimodFingolimod Hcl13$46,395
RexultiBrexpiprazole25$45,979
Rasagiline Mesylate99$29,297
BriviactBrivaracetam20$28,057
QuliptaAtogepant25$26,258
Memantine Hcl624$22,968

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$677$309,47728 claims
SanofiAubagio$24,512$170,38919 claims
AbbVieUbrelvy, Qulipta, Namzaric$120,656$154,254121 claims
NovartisGilenya$602$119,92312 claims
Teva Pharmaceuticals USA, Inc.Austedo$14,965$88,85012 claims
PfizerNurtec Odt$90$53,87842 claims
Otsuka America Pharmaceutical, Inc.Rexulti$39$45,97925 claims
UCB, Inc.Briviact$795$28,05720 claims
Upsher-smith Laboratories LLCTopiramate$19$4,963238 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 474 neurology providers in Virginia.

Other neurology in Mechanicsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →